🇺🇸

US SEC Filing Intelligence

· daily

Nasdaq 100 Stocks SEC Filings — March 03, 2026

Across 10 SEC 8-K filings from NASDAQ-100 constituents on March 3, 2026, dominant themes include capital raising via at-the-market (ATM) offerings by TXNM Energy ($125M) and Canton Strategic Holdings/Tharimmune ($300M), signaling liquidity bolstering amid neutral sentiment; executive transitions at Intel (Chair retirement), J.M. Smucker (COO separation), and Community West Bancshares (COO retirement); and biotech advancements with Immunome's 27% YoY net loss improvement to $212.4M, cash runway to 2028, and Phase 3 success (84% risk reduction, HR=0.16), alongside Adial's mixed Europe partnership potential (~$60M value). Period-over-period trends are limited but highlight Immunome's R&D expenses up 37% YoY to $177.3M and collaboration revenue down 23% to $6.9M, contrasting sharply improved loss per share ($(2.43) vs. $(5.00)). No insider trading activity reported across filings, but TXNM's 2026 incentive plans tie bonuses to EPS thresholds (up to 230% salary) and LTIP to earnings growth/FFO metrics through 2028, aligning management. Portfolio-level patterns show dilution risks from ATMs (total ~$425M potential), offset by Immunome's strong pipeline catalysts and Adial's commercialization pathway, with neutral-to-mixed sentiment (6/10 neutral) implying stable but non-explosive near-term implications; investors should prioritize biotech catalysts over governance noise.

6 high priority 4 medium 10 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 03, 2026

Across 79 SEC filings from DJ30-related and associated US blue-chips on March 3, 2026, dominant themes include robust M&A activity (e.g., Select Medical $3.9B takeover at 18-25% premium, Flowco $200M Valiant acquisition), mixed Q4/FY2025 earnings with average revenue growth of ~20% YoY in reporting firms (e.g., EVgo +75% Q4, Limbach +24.7% FY) offset by widespread margin compression averaging -150bps (e.g., Mayville EBITDA margin 7.6% to 4.7%, Limbach gross 27.8% to 26.2%). Capital allocation leans shareholder-friendly with buybacks (Limbach $50M, Civeo 10% authorization, Kontoor $25M) and dividends (Versant $0.375/share), alongside debt refinancings improving terms (Vertiv investment-grade upgrade, Adtalem lower margins). Forward guidance for 2026 shows cautious optimism with revenue growth projections of 5-15% in most (e.g., CrowdStrike ARR to $6.47-6.52B +24% implied), but flat/declining EBITDA in others (EVgo -$20M to $20M). Insider activity is minimal but neutral (e.g., Innventure tax withholdings), with no major sells signaling conviction. Portfolio-level trends flag healthcare/tech outperformance vs. cyclical softness in manufacturing/energy, with 12/79 filings highlighting spin-offs/divestitures (Honeywell Aerospace, Ziff Davis $1.2B Connectivity sale) as deleveraging catalysts. Overall, actionable alpha lies in M&A premiums and guidance beats amid tariff/inflation risks.

31 high priority 48 medium 79 total filings
· daily

US SEC Filings Daily Market Digest — March 03, 2026

Across 385 SEC filings for March 3, 2026, healthcare and biotech dominate with 45+ earnings/milestones showing mixed YoY revenue growth averaging +25% (e.g., Rigel +41%, Strata Critical +83.5%) but persistent net losses narrowing in 60% of cases; retail reports mixed comp sales (-2.5% Target to +9% Ross Stores) with margin expansion in resilient names (Best Buy +360bps to 5.2%). M&A activity surges with 15+ deals (e.g., Select Medical $16.50/share premium, RAPT $58/share acquisition), while financings/debt issuances exceed 50 (e.g., TXNM $125M ATM, Reinsurance Group $400M notes). Capital returns strong: 20+ dividends/buybacks (Best Buy div +1%, Pinterest $2B repurchases). Portfolio trends: margins compress in 7/15 industrials (-150bps avg) but expand in consumer/health (+200bps avg); insider conviction low volume but positive (e.g., no major sells). Neutral ETF/prospectus filings (120+) signal routine compliance. Forward catalysts cluster mid-2026 (Phase 3 data, mergers). Overall, bullish on healthcare catalysts, cautious retail/debt-heavy names amid going concern flags (3 cases).

207 high priority 178 medium 385 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 03, 2026

Across 50 filings from the S&P 500 Consumer Discretionary stream (broadly including retail, autos, and adjacent), sentiment is mixed-positive with 18 positive, 12 mixed, 10 neutral, and few negative, driven by robust M&A (e.g., Flowco $200M, Cal-Maine $130M, Ziff Davis $1.2B divestiture) and capital returns (Ross Stores $2.55B buyback +21%, MarketWise $0.45 total dividend), offsetting earnings pressures. Period-over-period trends show retail sales growth averaging +7% YoY in outperformers like Ross (+12%) and AutoZone (+8%) but declines in Target (-1.5%) and B&G Foods (-2.2%), with margin compression widespread (-137bps AutoZone, -260bps L.B. Foster). Capital allocation leans shareholder-friendly (dividend hikes, buybacks, debt refinancings lowering costs like HA Sustainable 8% to 7.125%), while forward guidance is cautious (Target ~2% sales growth, Ross 3-4% comps). Insider conviction absent in most but supported by 10b5-1 plans (Smart Sand) and board expansions. Key implications: tactical buys in strong retail comps amid M&A wave, watch margin trends and Q1 catalysts for portfolio rotation.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 03, 2026

Across 17 SEC filings from the USA S&P 500 Healthcare stream (including biotech, pharma, providers, and tangential sectors), key themes include positive regulatory milestones and M&A approvals in biotech (e.g., FDA Priority Review, merger votes), mixed financial results with revenue growth in some (Prime Medicine +55% YoY) offset by widening losses (CalciMedica net loss +116% YoY), aggressive capital returns via buybacks (Roivant $1B new program, Civeo new 10% authorization), and leadership transitions (Cigna CEO retirement, Protagenic new President). Period-over-period trends show 3/5 reporting companies with YoY revenue growth (avg +29%) but 4/5 with wider net losses (avg +42%), highlighting R&D intensity in biotech; Australian operations boosted Civeo Q4 EBITDA +90% YoY. Critical developments like Roivant's $2.25B Moderna settlement and Ventyx's 96% merger approval signal liquidity boosts and strategic exits, while trial setbacks (CalciMedica) flag risks. Portfolio-level patterns reveal biotech conviction via capital allocation (buybacks up) amid cash runways into 2027, positioning sector for catalysts but vulnerable to clinical risks.

4 high priority 13 medium 17 total filings
· daily

Global High-Priority Regulatory Events — March 03, 2026

Across 236 filings dominated by US SEC 8-Ks and routine fund prospectus certifications (497J/K ~60%), critical themes include robust M&A/takeover activity (e.g., Select Medical $3.9B EV at 25% premium, Flowco $200M acquisition, Knightscope bolt-on), leadership transitions (positive in Byrna, Wyndham; neutral elsewhere), and capital raises/refinancings (TXNM $125M ATM, Leidos $1.4B notes for ENTRUST). Period trends show mixed revenue growth: Evolus Q4 +14% YoY/$90.3M, Black Rock Coffee Q4 +25.3% YoY/$53.6M but FY net loss -130% to $16.5M; margins compressed in some (RYAM Q4 EBITDA -$5M YoY). Indian firms faced clustered SEBI fines for board non-compliance (e.g., Bharat Heavy, Hindustan Copper ~₹5-10L each, 10+ cases), signaling governance risks. Forward guidance stable/positive (Evolus 10-13% rev growth 2026, Wyndham reaffirmed), with capital returns via dividends (Mangalore ₹4/share, 40%, record Mar 11), buybacks (Pinterest $2B H1 2026), and debt optimization (Reinsurance $396M net, Vertiv IG upgrade). Portfolio-level: Healthcare M&A bullish, energy financings neutral, funds neutral (low materiality). Implications: Tactical opportunities in take-private premiums, monitor Indian governance for shorts, favor US growth names amid stable guidance.

236 high priority 236 total filings
· daily

US Executive Officer Management Changes SEC — March 03, 2026

Across 32 filings on US executive and director changes dated March 3, 2026, dominant themes include orderly planned retirements and successions (e.g., Cigna, Energy Fuels, Nucor), experienced appointments (e.g., Wyndham CFO, Massimo CFO, Protagenic President), and compensatory updates (severance plans, bonuses, LTIPs in 12 firms), with 14 positive, 12 neutral, and 4 mixed sentiments signaling management stability amid sector diversity from banking to biotech and energy. Period-over-period trends highlight outliers like Black Rock Coffee's Q4 2025 revenue +25.3% YoY and SSS +9.3%, Byrna's 84% CAGR revenue growth since 2019, and CigNA's revenue expansion from $18B to $275B (+1428% over 17 years) with +750% TSR, contrasting Prairie Operating's leadership vacuum. No widespread insider selling noted, but capital allocation via debt repayment (Black Rock reduced term loan by $30.1M) and equity grants (e.g., Target Hospitality PSUs up to 200% vesting) supports shareholder alignment. Forward-looking reaffirmations (Wyndham, Cigna 2026 outlooks) and guidance (Black Rock FY2026 revenue $255-257M, EBITDA $33.5-34.5M) indicate confidence, though interim CEOs (Prairie) flag transition risks. Portfolio implications favor long-term holders in growth firms with smooth handovers, monitoring oil/gas for leadership gaps.

32 high priority 32 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 03, 2026

Across 44 filings in the USA Corporate Distress & Bankruptcy stream, overarching themes include proactive debt refinancing and covenant relief (e.g., 10+ amendments/extensions providing liquidity runway), healthcare/biotech M&A and settlements amid distress signals (12 filings), and equity raises/buybacks signaling confidence in select names despite Nasdaq deficiencies and delistings (4 cases). Period-over-period trends are sparse but reveal mixed revenue performance: Evolus +14% YoY Q4/+12% FY 2025 revenue with GAAP profitability in Q4, contrasting RYAM's -1% YoY Q4 sales and worsening $21M loss; no broad margin compression but operational cash strains in 3 names (e.g., RYAM -$88M Adj FCF). Critical developments: Trinseo NYSE delisting (immediate suspension), Karyopharm going concern doubt tied to $25M equity raise by June 2026, and Arbutus/Genevant $2.25B Moderna settlement (upfront July 2026). Portfolio-level patterns show 15/44 positive sentiments (refinancings, acquisitions), 8 negative (delistings, deficiencies), with healthcare (18/44) dominant for distress signals but also opportunities; implications favor monitoring liquidity extensions as buyout catalysts while avoiding delisting risks.

44 high priority 44 total filings
· daily

US SEC Trading Suspension Halt Orders — March 03, 2026

Three US-listed companies—Trinseo PLC (NYSE), PDS Biotechnology Corp (Nasdaq), and CVR Partners LP (NYSE)—face critical listing compliance deficiencies announced in early March 2026, signaling heightened delisting risks amid weak market caps, share prices, and governance structures. Trinseo faces immediate trading suspension and delisting due to average market cap below $15M over 30 days, following prior December 2025 warnings for $50M equity thresholds and sub-$1 share price. PDSB received a Nasdaq notice for 30 consecutive days below $1.00 bid price, with 180 days to comply via potential reverse split. CVR Partners disclosed audit committee non-compliance after director death, reducing independents below NYSE Section 303A.07(a) requirements. No period-over-period financial trends available, but persistent low market caps and prices indicate deteriorating shareholder value and liquidity. Portfolio-level pattern: Small-cap distress with immediate (Trinseo) to medium-term (PDSB, CVR) catalysts for suspensions/delistings, implying sector-agnostic compliance failures in chemicals, biotech, and fertilizers.

3 high priority 3 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 03, 2026

Across 31 SEC filings on USA Board Room Changes from March 3, 2026, a dominant theme is orderly leadership transitions with 12 CEO/President/CFO appointments or promotions highlighting experienced hires (e.g., Byrna, Wyndham, Cigna, Massimo), 10 retirements/resignations without disagreements (e.g., Nucor, PCA, Northpointe), and 5 interim roles signaling searches (Prairie Operating). Positive sentiment prevails in 14 filings (45%), driven by growth legacies like Cigna's 750% TSR and Byrna's 84% CAGR revenue growth from $0.25M to $118M, while mixed/neutral tones in 15 reflect change-of-control (Slam Corp) or vague details (ACRG). Period trends show outliers like Black Rock Coffee's Q4 2025 revenue +25.3% YoY and SSS +9.3%, but FY net loss widened 130.1%; Wyndham boasts 20 straight quarters of net room growth. No broad insider selling/buying patterns, but capital allocation via equity grants (e.g., Protagenic 1% dilution, Target Hospitality PSUs) and severance enhancements (Group 1, Simmons) indicate retention focus amid no major guidance cuts—Wyndham/Cigna reaffirmed 2026 outlooks. Portfolio implications favor monitoring healthcare/energy for succession stability boosting TSR, while small-caps risk interim leadership gaps.

31 high priority 31 total filings
· daily

US Merger & Acquisition SEC Filings — March 03, 2026

The 7 filings reveal a vibrant USA M&A and takeover landscape dominated by SPAC activity (4/7 filings), with two fresh IPOs raising $225M combined ($100M APEX, $125M Clearthink), one extension to March 2027 with near-zero redemptions (Piermont), and operational funding via $1.5M note (Valuence), signaling investor appetite for blank-check vehicles amid no explicit YoY/QoQ financial trends but strong forward momentum. Strategic tuck-ins shine with Knightscope's acquisition of EBITDA-positive Event Risk LLC (double-digit growth, Fortune 1000 clients), poised for revenue density via robotics integration, while Duke Energy locks in $2.8B initial minority stake from Brookfield (phased to $6B total by 2028, 19.7% ownership). RAPT Therapeutics flags a bearish privatization/delisting with drastic share reduction to 1,000 and control shifts. Positive sentiment prevails (5/7 filings), with materiality at 9/10 for most, highlighting M&A as a key growth lever; no insider trades noted but capital inflows underscore conviction. Portfolio implication: overweight SPACs and acquisitive tech/energy for near-term catalysts like GSX conference and phased closings.

7 high priority 7 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 03, 2026

Overnight SEC filings (626 total) dominated by routine 497K/J fund prospectuses (95%+ volume) showing pervasive mixed/neutral sentiment with most active funds underperforming S&P 500 benchmarks long-term (e.g., 10/12 Hennessy funds trailed 14.82% 10Y return avg by 200-500bps) amid high turnover (avg 80%) and sector concentrations, signaling caution on active mid/small-cap strategies vs passive indices. Operational companies highlighted positive milestones like Aptera's first vehicle production (+8/10 materiality) and Byrna's revenue 84% CAGR under retiring CEO, but mixed earnings (Limbach rev +25% YoY yet GCR -7%, AutoZone SSS +3.3% but margins -137bps). Biotech M&A active (Rallybio/Candid $750M rev merger diluting legacy holders to 3.65%; Freenome de-SPAC H1 2026) with positive pipeline catalysts; SPAC/control changes (Slam Corp full equity shift to crypto/DeFi experts). Capital allocation bullish in repurchases (NRG $300M, BrightSpring $60M potential) but insider selling patterns in funds/mixed signals. Portfolio trend: margin compression avg -100bps in 6/10 detailed earnings despite rev growth +15% avg YoY; forward catalysts cluster Q2 2026 (FDA nods, mergers). Implications: favor passive ETFs/index hugging, monitor biotech/SPAC dilutions, buy dips in infra/energy acquirers.

568 high priority 58 medium 626 total filings
· daily

Significant Contract Modifications ($10M+) — March 02, 2026

A single $253,723 firm-fixed-price contract to Lockheed Martin from NASA Goddard underscores neutral, low-materiality activity in space R&D for Mars end-to-end service architectures. The 3-month performance period (Mar-May 2026) with $0 outlays limits near-term revenue visibility and portfolio impact. This isolated award aligns with NASA's Mars focus but signals no broader trends warranting immediate position changes.

1 total filings
· daily

Contract Deobligations Alert — March 02, 2026

A single $253,723 NASA contract to Lockheed Martin for Mars end-to-end service architectures reflects modest early-stage R&D commitment in space exploration. Neutral signal due to small value (0.0002% of LMT's ~$130B FY25 guidance), firm-fixed pricing, zero outlays, and 3-month duration limiting near-term revenue impact. Monitor for follow-on potential amid NASA's Mars focus, but materiality remains low for institutional portfolios.

1 total filings
· daily

Contract Option Exercises — March 02, 2026

NASA awarded Lockheed Martin a $253,723 firm-fixed-price contract for Mars end-to-end service architecture research, a neutral signal given its small scale relative to LMT's $67B+ annual revenue. The 3-month performance period (Mar-May 2026) with $0 outlays to date limits immediate revenue impact but underscores NASA's continued Mars R&D focus via full-and-open competition. No broader patterns emerge from this single record, warranting monitoring for follow-on awards.

1 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 02, 2026

Across 34 diverse SEC filings labeled under S&P 500 Consumer Staples (though spanning energy, tech, biotech, REITs, media), overarching themes reveal mixed sentiment with robust revenue growth in 9/18 reporting companies averaging +18% YoY (e.g., MongoDB +27%, Helios +17% Q4), offset by declines in 6 averaging -4% YoY (Alamo -3%, Mobile Infra -4.3%) and margin compression in 7/15 cases by -130bps avg (Alamo -140bps Q4, Great Elm NAV -20% QoQ). Capital allocation shines with buybacks totaling >$430M (ADMA $200M, Proficient $15M, DiamondRock $37M past) and dividends hikes (Alamo +13.3%, Helios 116 qtrs), signaling management conviction amid $2.5B+ in M&A/debt moves (Paramount $81B, Kosmos $220M sale). Insider activity sparse but mixed at Coca-Cola Europacific (exec sales $1.4M offset by routine buys). Forward-looking data flags modest growth guidance in 6 firms (midpoints +4-7%) and catalysts like satellite launches (AST Q1 2026). Critical risks include Elevance Health CMS sanctions (Mar 31) and impairments (Kosmos $178M), while portfolio trends point to resilient cash flows (Helios record $127M FY) supporting returns. Implications: Bullish on capital return plays and growth outliers, bearish on reg/impaired names; sector shows defensive buyback trends despite macro pressures.

15 high priority 19 medium 34 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 02, 2026

Across 71 SEC filings from the USA S&P 500 Industrials stream and related sectors, overarching themes include robust M&A activity (12+ completions like ITT's $4.8B SPX FLOW acquisition and bank mergers boosting assets 20-42% YoY), strong revenue growth in energy/industrials (e.g., Venture Global +177% YoY to $13.8B, Federal Signal +17% to $2.18B), but mixed profitability with 6/15 high-materiality reports showing EPS/net income declines (avg -50% YoY). Period-over-period trends reveal YoY revenue acceleration averaging +40% in growth outperformers (10 filings >50%), offset by margin compression in 7 cases (avg -150bps, e.g., Sturm Ruger gross profit -29%), alongside positive capital returns ($500M+ buybacks/dividends across 8 firms). Critical developments: Guidance cuts (Whirlpool EPS -14% to $6), raises (Xeris +30% to $375-390M), defense hires (L3Harris/Eaton CFOs), and Phase 3 catalysts (EyePoint/Rhythm PDUFA Mar 20). Portfolio-level patterns signal industrial consolidation via M&A (ITT/Federal Signal), resilient cash flows (Tidewater FCF $426M), but watch profitability volatility and delistings (Graphjet). Market implications favor M&A plays and growth industrials, with caution on consumer/manufacturing slowdowns.

37 high priority 34 medium 71 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 02, 2026

Across the 7 filings in the USA S&P 500 Energy intelligence stream, key themes include proactive capital allocation with debt refinancings (Targa's $1.5B notes issuance, Peapack's $100M notes redemption), share repurchases (XOMA's $16M buyback reducing shares 5%), and M&A progress (Baker Hughes' Chart Industries merger financials filing), alongside governance resolutions (Dorchester's Nasdaq compliance fix) and mixed biotech updates (XOMA royalties ~$49-50M FY2025 prelim, Bioxytran trial). Period-over-period insights are limited but highlight XOMA's robust FY2025 royalty receipts ($22.5M Wet AMD/DME/RVO YTD, up via new 24 assets added) vs no broad YoY declines noted; energy firms show balance sheet strengthening without margin compression signals. Critical developments imply sector resilience with Targa's positive sentiment (9/10) signaling growth funding, Baker's neutral M&A advancement (7/10 materiality), and Dorchester's compliance closure reducing overhangs. Portfolio-level patterns reveal 3/7 filings with capital returns/raises (avg materiality 8.7/10), favoring bullish positioning amid stable operations. No insider selling patterns detected; forward-looking catalysts cluster in XOMA's 2026 pipeline (e.g., Seralutinib data, ersodetug approvals). Market implications: Energy players like Targa/Baker prioritize capex/deals, actionable for long positions pre-catalysts.

2 high priority 5 medium 7 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 02, 2026

Across 304 SEC filings from S&P 500 Financials and broader US equities (though heavily skewed to biotech, energy, and industrials), overarching themes include robust revenue growth averaging +25% YoY in high-materiality reporters (e.g., Venture Global +177%, Astrana Health +56%), but widespread margin compression (-100 to -200 bps average in 12/20 mixed sentiment filers like Sturm Ruger, Plug Power) and mixed profitability amid rising OpEx/R&D. Financials show shareholder-friendly capital allocation with dividend hikes (Amex +15.9%, PROG +7.7%) and buybacks (Klaviyo $500M, ADMA $200M), while biotech dominates forward-looking catalysts (20+ Phase 2/3 readouts H1-H2 2026). M&A activity surges (30+ deals, e.g., Warner Bros $81B, Malibu Boats accretive), insider conviction mixed (Coca-Cola exec sales $1.4M but small buys), and guidance largely raised (e.g., Lumexa +3-8%, Xeris +30%). Portfolio-level trends: 65/304 positive sentiment, revenue YoY up in 180/304, but net losses in 40% due to impairments/restructurings; net leverage improving in 15 BDCs/REITs (avg 1.5-3x). Implications: Bullish for growth sectors with catalysts, cautious on margins/expenses; actionable now on dividend payers and H1 biotech events.

125 high priority 179 medium 304 total filings
· daily

US Material Events SEC 8-K Filings — March 02, 2026

Across 112 SEC filings from March 2, 2026, a dominant theme is aggressive M&A activity, particularly in banking (10+ mergers like HBT Financial, Farmers National, First Mid Bancshares) expanding assets 20-42% and footprints, signaling sector consolidation amid stable rates. Biotech/pharma sees 15+ deals/financings (e.g., Zymeworks $250M royalty note, Gyre-Cullgen $300M merger, Kairos CL-273 license) bolstering pipelines with FY2027 revenue projections up to $200M+. Strong period trends include revenue growth in tech (MongoDB +27% YoY Q4 FY2026 to $695M, Dave Inc +62% YoY Q4 2025 to $164M) and production upticks (Kosmos +4% QoQ to 67.9k boepd), though mixed with impairments/losses; capital allocation favors accretive buybacks/dividends (Zymeworks stock repurchases, Great Elm $0.30/share Q1 dividend). Leadership churn is high (30+ appointments/retirements) but mostly orderly/positive, enhancing expertise in finance/risk. Energy firms like Kosmos/Tilray pursue accretive asset deals ($220M EG sale, BrewDog acquisition for $200M rev), while SPACs/offerings (Illumination $200M IPO, Fortress $250M) indicate bull market for listings. Overall bullish M&A momentum (25+ deals) outweighs risks like restructurings (BioAtla 70% layoffs), positioning investors for catalysts in Q2-Q3 2026 closings.

112 high priority 112 total filings